Here’s Why CareDx Inc (CDNA), Netflix Inc. (NFLX) and Three Other Stocks Are Losing Ground Today

Skechers USA Inc (NYSE:SKX)’s stock is over 9% in the red after analysts at Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight’ and slashed the price target to $25 f$41 to $25. The analyst report suggested that the company will face low demand in the coming months. The number of funds from our database long Skechers USA declined to 27 from 32 during the second quarter, while the aggregate value of their positions fell to $424 million from $477 million and represented 9% of its outstanding stock.

Follow Skechers Usa Inc (NYSE:SKX)

Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s stock has lost over 10% since the opening bell. Earlier today, Wedbush reaffirmed its ‘Outperform’ rating and $109 price target on Pacira Pharmaceuticals. In other news, also today the company has announced the launch of its EXPAREL® (bupivacaine liposome injectable suspension) to the oral surgeon community. The product is a local analgesic that can be used in postsurgical pain control. Among the funds we track, 26 funds held $253 million worth of Pacira Pharmaceuticals’s stock in aggregate at the end of June, having amassed 20.20% of its outstanding stock, compared to 22 investors that owned $548 million worth of shares a quarter earlier.

Follow Pacira Biosciences Inc. (NASDAQ:PCRX)

Disclosure: none